Overview

Study of Narazaciclib (ON 123300) Plus Letrozole in Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer

Status:
Not yet recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

This study will assess the safety and efficacy of increasing doses of narazaciclib (ON 123300) in combination with the standard daily dose (2.5mg) of letrozole as second or third line treatment in patients with Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Onconova Therapeutics, Inc.

Treatments:

Letrozole